ArticleScientific reports2025
New insights into the range and transmission dynamics of a koala gammaherpesvirus, phascolarctid gammaherpesvirus 2.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current status and future directions ofFrontiers in veterinary science · 2026Pooled it
- The relationships of viral and protozoal co-infections to Chlamydia pecorum infection and chlamydiosis outcomes in northern koalas (Phascolarctos cinereus).PLoS pathogens · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent classification of the koala to endangered across most of its range has emphasised the urgent need for enhanced disease surveillance. Little is known about the distribution and clinical significance of phascolarctid gammaherpesvirus 2 (PhaHV-2) outside the Australian states of Victoria and South Australia. PhaHV-2 may have significant impacts on koala wellbeing, justifying investigation into its distribution and impact. To better characterise virus distribution and factors associated with infection, we developed a novel quantitative polymerase chain reaction assay with a high sensitivity, specificity and throughput capacity, to facilitate rapid detection and quantification of PhaHV-2. We applied this assay to 157 predominantly clinically-derived, urogenital swab samples. Results indicated that the distribution of PhaHV-2 extends throughout the endangered New South Wales koala populations. Frequency of detection of PhaHV-2 was highest in South Australia (25%) and lowest in northern Qld (0%) and was more likely in older koalas than younger koalas. We corroborate previous findings of an association with presence of PhaHV-1 and find no evidence to support sex as a predictor for viral presence in clinically-derived samples. The capacity to rapidly detect mucosal shedding of PhaHV-2 will enable rapid isolation of affected individuals and aid further research into the pathophysiological impacts of this virus in koalas and the influence of co-infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.